Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Oppenheim, B. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oppenheim, B. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy, Vol 41, 7-11, Copyright © 1998 by The British Society for Antimicrobial Chemotherapy

ORIGINAL ARTICLES

The changing pattern of infection in neutropenic patients

BA Oppenheim
Public Health Laboratory, Withington Hospital, West Didsbury, Manchester, UK.

Over the past 20 years there has been a dramatic shift in the pattern of infection in neutropenic patients. During the 1970s Gram-negative organisms caused approximately 70% of all bacteraemias, but by the late 1980s the situation had reversed and approximately 70% of bacteraemias were due to Gram-positive organisms. The main contributors to this increase in Gram-positive infections have been the coagulase-negative staphylococci and the viridans streptococci. More recently, enterococci have emerged as significant pathogens in this patient group, and the development of glycopeptide resistance in the enterococci is of particular concern since this class of antibiotics is widely used in neutropenic patients. Among Gram-negative organisms, the emergence of resistance to fluoroquinolones, particularly in Escherichia coli, is a worrying feature which may lead to a reassessment of the use of quinolone prophylaxis in this setting.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
C. Cattaneo, G. Quaresmini, S. Casari, M. A. Capucci, M. Micheletti, E. Borlenghi, L. Signorini, A. Re, G. Carosi, and G. Rossi
Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution
J. Antimicrob. Chemother., March 1, 2008; 61(3): 721 - 728.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
S. Mushtaq, M. Warner, A. P. Johnson, and D. M. Livermore
Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods
J. Antimicrob. Chemother., September 1, 2004; 54(3): 617 - 620.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
H. Giamarellou, H. P. Bassaris, G. Petrikkos, W. Busch, M. Voulgarelis, A. Antoniadou, E. Grouzi, and N. Zoumbos
Monotherapy with Intravenous Followed by Oral High-Dose Ciprofloxacin versus Combination Therapy with Ceftazidime plus Amikacin as Initial Empiric Therapy for Granulocytopenic Patients with Fever
Antimicrob. Agents Chemother., December 1, 2000; 44(12): 3264 - 3271.
[Abstract] [Full Text]

Home page
 J Antimicrob ChemotherHome page
J. M. Entenza, I. Caldelari, M. P. Glauser, and P. Moreillon
Efficacy of levofloxacin in the treatment of experimental endocarditis caused by viridans group streptococci
J. Antimicrob. Chemother., December 1, 1999; 44(6): 775 - 786.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
G. Candiani, M. Abbondi, M. Borgonovi, G. Romano, and F. Parenti
In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic
J. Antimicrob. Chemother., August 1, 1999; 44(2): 179 - 192.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.